Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

07. April 2025 10:33 ET | Quelle: Research and Markets

Growth Trends, Competitive Strategies and Forecasts 2025-2033: Advancements in Additive Manufacturing, Growing Demand in Automotive and Aerospace, High Initial Investments

Dublin, April 07, 2025 (GLOBE NEWSWIRE) -- The "Powder Metallurgy Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts,...
07. April 2025 09:00 ET | Quelle: Janssen Cilag International NV

European Commission approves subcutaneous RYBREVANT®▼ (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer

Subcutaneous (SC) amivantamab offers patients greater convenience, reducing administration time from hours to minutes and with a five-fold reduction in infusion-related reactions compared to the IV...
07. April 2025 05:32 ET | Quelle: Janssen Cilag International NV

European Commission approves Johnson & Johnson’s subcutaneous DARZALEX® (daratumumab)-based quadruplet regimen for the treatment of patients with newly diagnosed multiple myeloma, regardless of transplant eligibility

Approval cements daratumumab as a foundational therapy in newly diagnosed multiple myeloma and the only anti-CD38 antibody for all patient types in this setting Phase 3 CEPHEUS study shows...
02. April 2025 04:26 ET | Quelle: Research and Markets

Investment Casting Industry Forecast Report 2025-2030; Projected to Reach US$22.42 Billion at 4.68% CAGR - Precision, Reliability, and Sustainability Key to Success in the Growing Market

Dublin, April 02, 2025 (GLOBE NEWSWIRE) -- The "Investment Casting Market by Process Type (Sodium Silicate Process, Tetraethyl Orthosilicate), Material Type (Ferrous Metals, Non-Ferrous Metals),...
28. März 2025 07:20 ET | Quelle: Janssen Cilag International NV

TREMFYA® (guselkumab) receives positive CHMP opinion for treatment of patients with moderately to severely active Crohn’s Disease

Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn’s disease 1,2,3 Beerse, Belgium (28 March 2025) – Johnson & Johnson today announced that the...
26. März 2025 11:50 ET | Quelle: Janssen Cilag International NV

RYBREVANT®▼ (amivantamab) plus LAZCLUZE®▼ (lazertinib) demonstrates significant overall survival benefit in patients with EGFR-mutated advanced non-small cell lung cancer versus osimertinib

Median overall survival not yet reached with a projected improvement of more than one year versus osimertinib*1BEERSE, BELGIUM, March 26, 2025 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a...
26. März 2025 05:09 ET | Quelle: Research and Markets

Asia-Pacific 3D Printing Market Forecast to Reach $32.8 Billion at an 18.4% CAGR - Metal 3D Printing Gaining Traction in Aerospace, Automotive, and Defence Industries

Dublin, March 26, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific 3D Printing Market Report and Forecast 2025-2034"has been added to ResearchAndMarkets.com's offering. The report looks into the market...
12. März 2025 07:34 ET | Quelle: Research and Markets

3D Printing Materials & Services Industry Report 2025-2030 - Surging Investments in 3D Bioprinting and Metal Additive Manufacturing Reshape Market Landscape

Dublin, March 12, 2025 (GLOBE NEWSWIRE) -- The "3D Printing Materials & Services Market - Focused Insights 2025-2030" report has been added to ResearchAndMarkets.com's offering.The 3D Printing...
28. Februar 2025 08:43 ET | Quelle: Janssen Cilag International NV

TREMFYA® (guselkumab) receives positive CHMP opinion for treatment of adult patients with moderately to severely active ulcerative colitis

Recommendation based on the findings from the Phase 3 QUASAR programme in ulcerative colitis1 Beerse, Belgium (28 February 2025) – Johnson & Johnson today announced that the Committee for...
28. Februar 2025 08:01 ET | Quelle: Janssen Cilag International NV

Johnson & Johnson’s DARZALEX® (daratumumab) subcutaneous-based regimen receives positive CHMP opinion for patients with newly diagnosed multiple myeloma, regardless of transplant eligibility

If approved, daratumumab will be the only anti-CD38 available for all patient types across newly diagnosed multiple myeloma, cementing daratumumab as a foundational therapy in the frontline setting. ...

Vorherige Seite

Nächste Seite